| |
| Device | Oncomine Dx Target Test (ODxT Test) |
| Generic Name | Next generation sequencing oncology panel, somatic or germline variant detection system |
| Applicant | Life Technologies Corporation 5781 Van Allen Way Carlsbad, CA 92008 |
| PMA Number | P160045 |
| Supplement Number | S029 |
| Date Received | 05/03/2021 |
| Decision Date | 09/15/2021 |
| Product Code |
PQP |
| Docket Number | 21M-1023 |
| Notice Date | 11/08/2021 |
| Advisory Committee |
Pathology |
| Clinical Trials | NCT02716116
|
| Supplement Type | Panel Track |
| Supplement Reason | Change Design/Components/Specifications/Material |
| Expedited Review Granted? | No |
| Combination Product | No |
| Predetermined Change Control Plan Authorized | No |
Approval Order Statement Approval to expand the intended use of the Oncomine Dx Target Test to include a companion diagnostic indication for the detection of EGFR exon 20 insertion mutations in non-small cell lung cancer patients who may benefit from the treatment with EXKIVITY (mobocertinib). |
| Approval Order | Approval Order |
| Summary | Summary of Safety and Effectiveness |
| Labeling | Labeling Labeling Part 2 |